SG10202107388VA - Non-human animals expressing ph-sensitive immunoglobulin sequences - Google Patents
Non-human animals expressing ph-sensitive immunoglobulin sequencesInfo
- Publication number
- SG10202107388VA SG10202107388VA SG10202107388VA SG10202107388VA SG10202107388VA SG 10202107388V A SG10202107388V A SG 10202107388VA SG 10202107388V A SG10202107388V A SG 10202107388VA SG 10202107388V A SG10202107388V A SG 10202107388VA SG 10202107388V A SG10202107388V A SG 10202107388VA
- Authority
- SG
- Singapore
- Prior art keywords
- human animals
- immunoglobulin sequences
- animals expressing
- sensitive
- sensitive immunoglobulin
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 241001465754 Metazoa Species 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261612126P | 2012-03-16 | 2012-03-16 | |
US201261611950P | 2012-03-16 | 2012-03-16 | |
US201261613352P | 2012-03-20 | 2012-03-20 | |
US201261736930P | 2012-12-13 | 2012-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202107388VA true SG10202107388VA (en) | 2021-08-30 |
Family
ID=48045752
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201700360VA SG10201700360VA (en) | 2012-03-16 | 2013-03-15 | Non-human animals expressing ph-sensitive immunoglobulin sequences |
SG11201405171WA SG11201405171WA (en) | 2012-03-16 | 2013-03-15 | Non-human animals expressing ph-sensitive immunoglobulin sequences |
SG10202107388VA SG10202107388VA (en) | 2012-03-16 | 2013-03-15 | Non-human animals expressing ph-sensitive immunoglobulin sequences |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201700360VA SG10201700360VA (en) | 2012-03-16 | 2013-03-15 | Non-human animals expressing ph-sensitive immunoglobulin sequences |
SG11201405171WA SG11201405171WA (en) | 2012-03-16 | 2013-03-15 | Non-human animals expressing ph-sensitive immunoglobulin sequences |
Country Status (24)
Country | Link |
---|---|
US (4) | US9801362B2 (en) |
EP (2) | EP3539374A1 (en) |
JP (4) | JP6228589B2 (en) |
KR (3) | KR102345232B1 (en) |
CN (2) | CN104302171B (en) |
BR (1) | BR112014022855A2 (en) |
CA (1) | CA2865645A1 (en) |
CY (1) | CY1121864T1 (en) |
DK (1) | DK2825037T3 (en) |
ES (1) | ES2737990T3 (en) |
HK (1) | HK1200270A1 (en) |
HR (1) | HRP20191333T1 (en) |
HU (1) | HUE045537T2 (en) |
IL (4) | IL234237B (en) |
LT (1) | LT2825037T (en) |
MX (2) | MX355944B (en) |
NZ (3) | NZ712508A (en) |
PL (1) | PL2825037T4 (en) |
PT (1) | PT2825037T (en) |
RS (1) | RS59076B1 (en) |
RU (2) | RU2664473C2 (en) |
SG (3) | SG10201700360VA (en) |
SI (1) | SI2825037T1 (en) |
WO (1) | WO2013138712A1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
SI2202245T1 (en) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
PL2275443T3 (en) | 2008-04-11 | 2016-05-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
MX365235B (en) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly. |
EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
CN104080909A (en) | 2011-11-30 | 2014-10-01 | 中外制药株式会社 | Drug containing carrier into cell for forming immune complex |
NZ712508A (en) | 2012-03-16 | 2018-06-29 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
CA2865644A1 (en) * | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
RS57414B1 (en) | 2012-03-16 | 2018-09-28 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
EP2882778B1 (en) * | 2012-08-13 | 2018-04-11 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
EP2940135B9 (en) | 2012-12-27 | 2021-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
MY185881A (en) * | 2013-02-20 | 2021-06-14 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
CN113621057A (en) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc region variants |
US9738702B2 (en) * | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
EA201791366A1 (en) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | ANTIBODIES TO C5 AND METHODS OF THEIR APPLICATION |
KR102650420B1 (en) | 2014-12-19 | 2024-03-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
WO2016117346A1 (en) * | 2015-01-22 | 2016-07-28 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
US9969800B2 (en) | 2015-02-05 | 2018-05-15 | Chugai Seiyaku Kabushiki Kaisha | IL-8 antibodies |
CN107438622A (en) * | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | Non-human animal of the selection with reference to the light chain variable district of antigen |
JP7019423B2 (en) | 2015-05-06 | 2022-02-15 | ヤンセン バイオテツク,インコーポレーテツド | Prostate-specific membrane antigen (PSMA) bispecific binder and its use |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
RU2763320C2 (en) * | 2016-01-13 | 2021-12-28 | Регенерон Фармасьютикалз, Инк. | Rodents having constructed section of heavy chain diversity |
JP7324583B2 (en) | 2016-05-20 | 2023-08-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Methods for breaking immune tolerance using multiple guide RNAs |
CN116458475A (en) | 2016-06-03 | 2023-07-21 | 瑞泽恩制药公司 | Non-human animals expressing exogenous terminal deoxynucleotidyl transferase |
EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
JP2021502967A (en) | 2017-11-14 | 2021-02-04 | 中外製薬株式会社 | Anti-C1s antibody and usage |
TWI842701B (en) | 2018-03-24 | 2024-05-21 | 美商再生元醫藥公司 | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
SG11202008620VA (en) | 2018-03-26 | 2020-10-29 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
SG11202008848XA (en) * | 2018-03-26 | 2020-10-29 | Regeneron Pharma | Anti-pfrh5 antibodies and antigen-binding fragments thereof |
CN108486126A (en) * | 2018-03-27 | 2018-09-04 | 重庆金迈博生物科技有限公司 | A kind of nucleic acid molecules and its application in humanized antibody |
KR102444180B1 (en) | 2018-06-14 | 2022-09-16 | 리제너론 파마슈티칼스 인코포레이티드 | Non-human animals capable of DH-DH rearrangement in the immunoglobulin heavy chain coding sequence |
KR20230066386A (en) | 2020-09-11 | 2023-05-15 | 리제너론 파마슈티칼스 인코포레이티드 | Identification and production of antigen-specific antibodies |
WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
US20220195014A1 (en) | 2020-12-23 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
WO2024056044A1 (en) * | 2022-09-16 | 2024-03-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals and methods for producing heavy-chain antibodies |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DE69130561T2 (en) | 1990-02-16 | 1999-06-24 | Boston Biomedical Research Institute, Inc., Boston, Mass. | Hybrid reagents with the ability to selectively release molecules into cells |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7067284B1 (en) | 1992-01-27 | 2006-06-27 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5999908A (en) | 1992-08-06 | 1999-12-07 | Abelow; Daniel H. | Customer-based product design module |
AU2466895A (en) * | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0843961B1 (en) | 1995-08-29 | 2007-01-24 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for constructing the same |
JP2007312792A (en) * | 1995-08-29 | 2007-12-06 | Kirin Pharma Co Ltd | Chimeric animals and method for producing the same |
SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
CA2305712A1 (en) | 1997-10-03 | 1999-04-15 | Chugai Seiyaku Kabushiki Kaisha | Natural humanized antibody |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
EP1317537B1 (en) | 2000-09-08 | 2006-12-20 | Massachusetts Institute Of Technology | G-csf analog compositions and methods |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
WO2003031656A1 (en) | 2001-10-05 | 2003-04-17 | United States Environmental Protection Agency | Genetic testing for male factor infertility |
CA2847885C (en) | 2001-11-30 | 2022-03-22 | Amgen Fremont Inc. | Transgenic animals bearing human ig.lambda. light chain genes |
AU2003256266A1 (en) | 2002-06-12 | 2003-12-31 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
EP2107116A3 (en) | 2002-06-12 | 2009-12-09 | Genencor International, Inc. | Methods for improving a binding characteristic of a molecule |
PT1523496E (en) | 2002-07-18 | 2011-09-29 | Merus B V | Recombinant production of mixtures of antibodies |
EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
WO2004065611A1 (en) | 2003-01-21 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of screening light chain of antibdoy |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
WO2005007696A2 (en) | 2003-07-15 | 2005-01-27 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
CN1560081A (en) | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | Preparing human source monoclone antibody by mouse capable of producing human IgGl weight chain-k light chain and application thereof |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
CN101724071A (en) * | 2004-10-08 | 2010-06-09 | 杜门蒂斯有限公司 | Single domain antibodies against TNFRl and methods of use therefor |
PL1802193T3 (en) | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Method for generating a mouse homozygous for a genetic modification |
EP1812065A4 (en) | 2004-10-22 | 2009-09-02 | Medimmune Inc | High affinity antibodies against hmgb1 and methods of use thereof |
RU2290442C2 (en) * | 2005-03-21 | 2006-12-27 | Всероссийский государственный научно-исследовательский институт животноводства (ВИЖ) | Method for in vivo transformation of animal testicle stem cells |
EP3195874A1 (en) * | 2005-03-25 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
WO2006117699A2 (en) | 2005-04-29 | 2006-11-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
EP1966241A2 (en) | 2005-12-05 | 2008-09-10 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
CA2638774C (en) | 2006-03-31 | 2015-11-24 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
MX2009003393A (en) | 2006-10-02 | 2009-05-11 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor. |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
CA2666511A1 (en) * | 2006-10-11 | 2008-04-17 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
RU2448979C2 (en) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Human antibodies to delta-like human ligand-4 |
CN101688228B (en) | 2007-03-13 | 2014-12-24 | 国家犾太健康中心 | Methods for generation of antibodies |
ITMI20071522A1 (en) | 2007-07-27 | 2009-01-28 | Areta Internat S R L | IDIOTYPIC VACCINE |
MX344415B (en) | 2007-09-14 | 2016-12-15 | Adimab Inc | Rationally designed, synthetic antibody libraries and uses therefor. |
SI2202245T1 (en) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
AU2008316661B2 (en) * | 2007-10-26 | 2013-05-23 | Oklahoma Medical Research Foundation | Monoclonal antibodies against activated and unactivated protein C |
PL2222706T5 (en) | 2007-12-14 | 2017-09-29 | Novo Nordisk As | Antibodies against human nkg2d and uses thereof |
CN102027123B (en) * | 2008-03-14 | 2016-03-16 | 人体酶有限公司 | The restructuring of end user's cell expression system produces reliable human protein |
PL2275443T3 (en) | 2008-04-11 | 2016-05-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
KR20110029156A (en) | 2008-06-27 | 2011-03-22 | 메뤼스 베.페. | Antibody producing non-human mammals |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
PL2346994T3 (en) | 2008-09-30 | 2022-04-19 | Ablexis, Llc | Knock-in mice for the production of chimeric antibodies |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
US20110314563A1 (en) | 2008-12-18 | 2011-12-22 | Kingdon Craig R | Antibody production |
RU2011149353A (en) | 2009-05-07 | 2013-06-20 | Вольво Констракшн Эквипмент Аб | WORKING MACHINE AND METHOD FOR MANAGING ITS WORK |
NZ596603A (en) | 2009-05-29 | 2013-07-26 | Morphosys Ag | A collection of antibodies or fragments having properties relevant to developability |
MX342623B (en) | 2009-06-26 | 2016-10-06 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format. |
HUE055817T2 (en) | 2009-07-08 | 2021-12-28 | Kymab Ltd | Animal models and therapeutic molecules |
BR112012001075B1 (en) | 2009-07-16 | 2020-12-01 | Wageningen Universiteit | METHODS FOR CHANGING THE CAPACITY OF A PLANT FOR ADAPTATION FOR CHANGES IN THE CONCENTRATION OF ZINC IN THE ENVIRONMENT, FOR PHYTOMMEDIATION AND BIOFORTIFICATION, AS WELL AS USE OF A NUCLEOTIDE WHICH CODES A BZIP19 AND / OR BZIP23 PROTEIN |
GB2472108B (en) * | 2009-08-27 | 2011-07-13 | Budha Singh Dhinjan | Wall bead |
CN102711449B (en) | 2009-12-10 | 2015-01-07 | 瑞泽恩制药公司 | Mice that make heavy chain antibodies |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
NZ719253A (en) | 2010-02-08 | 2022-08-26 | Regeneron Pharma | Common light chain mouse |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
BR112012022917A2 (en) | 2010-03-11 | 2017-01-10 | Pfizer | ph-dependent antigen binding antibodies |
TWI667257B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
EP2582230A1 (en) | 2010-06-17 | 2013-04-24 | Kymab Limited | Animal models and therapeutic molecules |
DK2480676T3 (en) | 2010-06-22 | 2016-06-20 | Regeneron Pharma | MICE EXPRESSING A HYDRIDE immunoglobulin light chain |
US8642835B2 (en) | 2011-02-25 | 2014-02-04 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
SG2014007686A (en) | 2011-08-05 | 2014-03-28 | Regeneron Pharma | Humanized universal light chain mice |
WO2013046722A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Ion concentration-dependent binding molecule library |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
SG11201405088QA (en) | 2012-03-06 | 2014-11-27 | Regeneron Pharma | Common light chain mouse |
CA2865644A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
RS57414B1 (en) | 2012-03-16 | 2018-09-28 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
NZ712508A (en) | 2012-03-16 | 2018-06-29 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
SG11201407644UA (en) | 2012-06-05 | 2014-12-30 | Regeneron Pharma | Methods for making fully human bispecific antibodies using a common light chain |
RU2636483C2 (en) | 2012-09-21 | 2017-11-23 | Реоксин Дискавериз Груп, Инк. | Cell for liquid electrolysis |
MY185881A (en) | 2013-02-20 | 2021-06-14 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
-
2013
- 2013-03-15 NZ NZ712508A patent/NZ712508A/en not_active IP Right Cessation
- 2013-03-15 JP JP2015500651A patent/JP6228589B2/en active Active
- 2013-03-15 DK DK13714127.1T patent/DK2825037T3/en active
- 2013-03-15 SG SG10201700360VA patent/SG10201700360VA/en unknown
- 2013-03-15 RU RU2014141307A patent/RU2664473C2/en not_active IP Right Cessation
- 2013-03-15 CA CA2865645A patent/CA2865645A1/en active Pending
- 2013-03-15 PT PT13714127T patent/PT2825037T/en unknown
- 2013-03-15 EP EP19156973.0A patent/EP3539374A1/en active Pending
- 2013-03-15 WO PCT/US2013/032036 patent/WO2013138712A1/en active Application Filing
- 2013-03-15 SG SG11201405171WA patent/SG11201405171WA/en unknown
- 2013-03-15 LT LTEP13714127.1T patent/LT2825037T/en unknown
- 2013-03-15 RU RU2018128915A patent/RU2018128915A/en not_active Application Discontinuation
- 2013-03-15 SG SG10202107388VA patent/SG10202107388VA/en unknown
- 2013-03-15 KR KR1020217003301A patent/KR102345232B1/en active IP Right Grant
- 2013-03-15 PL PL13714127T patent/PL2825037T4/en unknown
- 2013-03-15 MX MX2014011048A patent/MX355944B/en active IP Right Grant
- 2013-03-15 NZ NZ730271A patent/NZ730271A/en not_active IP Right Cessation
- 2013-03-15 HU HUE13714127A patent/HUE045537T2/en unknown
- 2013-03-15 NZ NZ629077A patent/NZ629077A/en not_active IP Right Cessation
- 2013-03-15 ES ES13714127T patent/ES2737990T3/en active Active
- 2013-03-15 US US13/834,129 patent/US9801362B2/en active Active
- 2013-03-15 EP EP13714127.1A patent/EP2825037B1/en active Active
- 2013-03-15 RS RS20190989A patent/RS59076B1/en unknown
- 2013-03-15 CN CN201380025818.2A patent/CN104302171B/en active Active
- 2013-03-15 CN CN201710192722.5A patent/CN107361011B/en active Active
- 2013-03-15 KR KR1020217042563A patent/KR102459666B1/en active IP Right Grant
- 2013-03-15 SI SI201331533T patent/SI2825037T1/en unknown
- 2013-03-15 BR BR112014022855A patent/BR112014022855A2/en not_active Application Discontinuation
- 2013-03-15 KR KR1020147025405A patent/KR102213535B1/en active IP Right Grant
- 2013-11-20 US US14/085,424 patent/US9648856B2/en active Active
-
2014
- 2014-08-21 IL IL234237A patent/IL234237B/en active IP Right Grant
- 2014-09-12 MX MX2021000484A patent/MX2021000484A/en unknown
-
2015
- 2015-01-29 HK HK15101009.0A patent/HK1200270A1/en unknown
-
2016
- 2016-02-10 IL IL244098A patent/IL244098B/en active IP Right Grant
-
2017
- 2017-05-10 JP JP2017093832A patent/JP6574811B2/en active Active
- 2017-09-13 US US15/703,490 patent/US11224207B2/en active Active
-
2018
- 2018-08-02 JP JP2018145734A patent/JP7011549B2/en active Active
-
2019
- 2019-01-21 IL IL264362A patent/IL264362B/en active IP Right Grant
- 2019-07-23 HR HRP20191333TT patent/HRP20191333T1/en unknown
- 2019-08-01 CY CY20191100821T patent/CY1121864T1/en unknown
-
2020
- 2020-04-27 IL IL274268A patent/IL274268B/en unknown
- 2020-10-16 JP JP2020174432A patent/JP2021007409A/en active Pending
-
2021
- 2021-12-08 US US17/545,099 patent/US20220217955A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274268A (en) | Non-human animals expressing ph-sensitive immunoglobulin sequences | |
HK1258227A1 (en) | Non-human animals with modified immunoglobulin heavy chain sequences | |
IL262958A (en) | Non-human animals having a humanized signal-regulatory protein gene | |
IL243581A0 (en) | Lincrna-deficient non-human animals | |
HK1212552A1 (en) | Gene knock-in non-human animal | |
EP2767160A4 (en) | Chimeric non-human animal carrying human hepatocyte | |
GB201214337D0 (en) | Transgenic animal | |
GB201222163D0 (en) | Pet belle |